This NCI grant is for establishing Research Teams for the Pediatric In Vivo Testing Program (Ped-InVivo-TP). The grant’s purpose is to rigorously test pediatric anticancer drug candidates using genomically characterized preclinical models, generating reliable data. This data will inform the prioritization of new agents for childhood cancer clinical testing. The program facilitates a Public-Private Partnership to accelerate and broaden pediatric preclinical testing, engaging pharmaceutical companies. Applicants must have suitable pediatric cancer models and capacity to test 8-10 agents annually. Awardees will collaborate closely with the Ped-InVivo-TP Coordinating Center for all testing, analysis, and reporting.
Opportunity ID: 328810
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | RFA-CA-20-034 |
| Funding Opportunity Title: | NCI Pediatric In Vivo Testing Program (U01 Clinical Trial Not Allowed) |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | – |
| Funding Instrument Type: | Cooperative Agreement |
| Category of Funding Activity: | Education Health |
| Category Explanation: | – |
| Expected Number of Awards: | – |
| Assistance Listings: | 93.395 — Cancer Treatment Research |
| Cost Sharing or Matching Requirement: | No |
| Version: | Synopsis 1 |
| Posted Date: | Aug 26, 2020 |
| Last Updated Date: | Aug 26, 2020 |
| Original Closing Date for Applications: | Nov 09, 2020 |
| Current Closing Date for Applications: | Nov 09, 2020 |
| Archive Date: | Dec 15, 2020 |
| Estimated Total Program Funding: | – |
| Award Ceiling: | $450,000 |
| Award Floor: | – |
Eligibility
| Eligible Applicants: | Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Public and State controlled institutions of higher education Others (see text field entitled “Additional Information on Eligibility” for clarification) City or township governments Public housing authorities/Indian housing authorities Small businesses County governments Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education State governments For profit organizations other than small businesses Independent school districts Native American tribal organizations (other than Federally recognized tribal governments) Native American tribal governments (Federally recognized) Special district governments Private institutions of higher education |
| Additional Information on Eligibility: | Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession. |
Additional Information
| Agency Name: | National Institutes of Health |
| Description: | This Funding Opportunity Announcement (FOA) is for Research Teams to form the NCI Pediatric in Vivo Testing Program (henceforth termed the Ped-InVivo-TP). The Research Teams of the Ped-InVivo-TP will determine the activity of pediatric anticancer drug candidates using preclinical models relevant to the cancer(s) on which their team focuses (supported under this FOA) and will work in concert with the Ped-InVivo-TP Coordinating Center (supported under RFA-CA-20-041). The Research Teams will use genomically characterized pediatric cancer models to develop a rigorous preclinical testing program that will generate reliable data that can be used to inform new agent prioritization decisions for childhood cancer clinical testing. The Ped-InVivo-TP is envisioned as a way for NCI to support the Foundation for the National Institutes of Health (FNIH)-organized Public-Private Partnership (PPP) for pediatric preclinical testing. The PPP is being developed to accelerate the pace and to broaden the scope of pediatric preclinical testing of agents being developed for adult cancer indications. Pharmaceutical companies and representatives of regulatory agencies will also participate in the PPP. The Program Director(s)/Principal Investigator(s) [PD(s)/PI(s)] of the Ped-InVivo-TP Research Teams and Coordinating Center will be expected to serve on the Scientific Advisory Committee (SAC) of the FNIH PPP and will contribute to the SAC with regards to the research opportunities in their areas of expertise. This FOA invites applications from Research Teams that have developed panels of genomically characterized pediatric cancer models and that have the capacity for using their panels to test up to 8-10 agents per year. The Ped-InVivo-TP Awardees will work closely with the Ped-In Vivo-TP Coordinating Center in the testing of agents and in the analysis and reporting of testing results. |
| Link to Additional Information: | http://grants.nih.gov/grants/guide/rfa-files/RFA-CA-20-034.html |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
NIH OER Webmaster
FBOWebmaster@OD.NIH.GOV Email:FBOWebmaster@OD.NIH.GOV |
Version History
| Version | Modification Description | Updated Date |
|---|---|---|
Related Documents
There are no related documents on this grant.
Packages
| Agency Contact Information: | NIH OER Webmaster FBOWebmaster@OD.NIH.GOV Email: FBOWebmaster@OD.NIH.GOV |
| Who Can Apply: | Organization Applicants |
| Assistance Listing Number | Competition ID | Competition Title | Opportunity Package ID | Opening Date | Closing Date | Actions |
|---|---|---|---|---|---|---|
| FORMS-F | Use for due dates on or after May 25, 2020 | PKG00263157 | Oct 09, 2020 | Nov 09, 2020 | View |
Package 1
Mandatory forms
328810 RR_SF424_2_0-2.0.pdf
328810 PHS398_CoverPageSupplement_5_0-5.0.pdf
328810 RR_OtherProjectInfo_1_4-1.4.pdf
328810 PerformanceSite_2_0-2.0.pdf
328810 RR_KeyPersonExpanded_2_0-2.0.pdf
328810 PHS398_ResearchPlan_4_0-4.0.pdf
328810 PHSHumanSubjectsAndClinicalTrialsInfo_2_0-2.0.pdf
Optional forms
328810 RR_Budget_1_4-1.4.pdf
328810 RR_SubawardBudget30_1_4-1.4.pdf
328810 PHS398_ModularBudget_1_2-1.2.pdf
328810 PHS_AssignmentRequestForm_3_0-3.0.pdf
Share This Post, Choose Your Platform!
About the Author: osnqt
